Search alternatives:
_ we » _ wet (Expand Search), _ e (Expand Search), _ re (Expand Search)
_ fe » _ e (Expand Search)
decrease » increase (Expand Search)
_ we » _ wet (Expand Search), _ e (Expand Search), _ re (Expand Search)
_ fe » _ e (Expand Search)
decrease » increase (Expand Search)
-
1
Decreased Interfacial Dynamics Caused by the N501Y Mutation in the SARS-CoV-2 S1 Spike:ACE2 Complex
Published 2022“…By elucidating a mechanistic basis for the increased affinity of the N501Y mutant S1-RBD for ACE2, we believe that the results presented here will aid in developing therapeutic strategies against SARS-CoV-2 including designing of therapeutic agents targeting the ACE2-S1-RBD interaction.…”
-
2
Decreased methylglyoxal-mediated protein glycation in the healthy aging mouse model of ectopic expression of UCP1 in skeletal muscle
Published 2023“…We found both young and aged HSA-mUCP1 mice had decreased advanced glycation endproducts (AGEs) formed from MG, lysine-derived Nε(1-carboxyethyl)lysine (CEL) and arginine-derived hydroimidazolone, MG-H1, whereas protein glycation by glucose forming Nε-fructosyl-lysine (FL) was increased ca. 2-fold, compared to wildtype controls. …”
Get full text
Get full text
Get full text
article -
3
Decreased methylglyoxal-mediated protein glycation in the healthy aging mouse model of ectopic expression of UCP1 in skeletal muscle
Published 2023“…We found both young and aged HSA-mUCP1 mice had decreased advanced glycation endproducts (AGEs) formed from MG, lysine-derived Nε(1-carboxyethyl)lysine (CEL) and arginine-derived hydroimidazolone, MG-H1, whereas protein glycation by glucose forming Nε-fructosyl-lysine (FL) was increased ca. 2-fold, compared to wildtype controls. …”
-
4
Corrigendum: Decreased interfacial dynamics caused by the N501Y mutation in the SARS-CoV-2 S1 spike:ACE2 complex
Published 2022“…<p dir="ltr">Corrigendum: Decreased interfacial dynamics caused by the N501Y mutation in the SARS-CoV-2 S1 spike:ACE2 complex: Frontiers in Molecular Biosciences <a href="https://dx.doi.org/10.3389/fmolb.2022.846996" target="_blank">https://dx.doi.org/10.3389/fmolb.2022.846996</a>, published online 22 July 2022.…”
-
5
-
6
-
7
Assessment of aged biodegradable polymer-coated nano-zero-valent iron for degradation of hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX)
Published 2012“…BACKGROUND: This study reports on the effects of aging on suspension behavior of biodegradable polymer-coated nano-zero-valent iron (nZVI) and its degradation rates of hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) under reductive conditions. …”
Get full text
Get full text
article -
8
Decreased phosphodiesterase activities in cardiac hypertrophy
Published 2007“…There is limited information on the changes in cardiac cyclic nucleotide phosphodiesterases (PDE1 to PDE5) during hypertrophy and the functional consequences on the cAMP pathway. …”
Get full text
Get full text
Get full text
Get full text
article -
9
Metformin attenuates V-domain Ig suppressor of T-cell activation through the aryl hydrocarbon receptor pathway in Melanoma: In Vivo and In Vitro Studies
Published 2021“…Here, metformin significantly decreased VISTA and AHR levels in vitro and in vivo. …”
Get full text
Get full text
Get full text
article -
10
-
11
Soluble Neuropilin-1 Response to Hypoglycemia in Type 2 Diabetes: Increased Risk or Protection in SARS-CoV-2 Infection?
Published 2021“…<h3>Introduction</h3><p dir="ltr">Neuropilin-1(NRP1) is a cofactor that enhances SARS-CoV-2 coronavirus cell infectivity when co-expressed with angiotensin-converting enzyme 2(ACE2). …”
-
12
-
13
Sleeve Gastrectomy in Patients with Type 2 Diabetes: Anthropometric and Cardiometabolic Improvements at 1, 3, 5, 7, and 9 years—Are the Initial Benefits Sustained?
Published 2025“…We appraised the evolution of 20 outcomes at 1, 3, 5, 7, and 9 years.…”
-
14
LDL-C Targets in Secondary Prevention: How Low Should We Go?
Published 2019“…<h3>Abstract</h3><p dir="ltr">The benefits of lowering low-density lipoprotein cholesterol (LDL-C), mainly using high-intensity statin therapy, and its impact on decreasing the recurrence of atherosclerotic cardiovascular disease (ASCVD) in secondary prevention has been well established. …”
-
15
-
16
-
17
The molecular mechanisms of apoptosis accompanied with the epigenetic regulation of the NY-ESO-1 antigen in non-small lung cancer cells treated with decitabine (5-aza-CdR)
Published 2023“…Therefore, we investigated the molecular mechanisms accompanied with the epigenetic regulation of NY-ESO-1 in 5-Aza-CdR-treated NCI–H1975 cell line. …”
-
18
Decreased Expression and Activity of cAMP Phosphodiesterases in Cardiac Hypertrophy and Its Impact on β-Adrenergic cAMP Signals
Published 2009“…Methods and Results: Cardiac hypertrophy was induced in rats by thoracic aortic banding over a time period of 5 weeks and was confirmed by anatomic measurements and echocardiography. …”
Get full text
Get full text
Get full text
Get full text
article -
19
Follow up and comparative assessment of IgG, IgA, and neutralizing antibody responses to SARS-CoV-2 between mRNA-vaccinated naïve and unvaccinated naturally infected individuals ov...
Published 2023“…We measured the levels of neutralizing total antibodies (NtAbs), anti-S-RBD IgG, and anti-S1 IgA titers among VN and NI up to ∼10 months from administration of the first dose, and up to ∼7 months from SARS-CoV-2 infection, respectively. …”
Get full text
Get full text
Get full text
article -
20
A slow but steady nanoLuc: R162A mutation results in a decreased, but stable, nanoLuc activity
Published 2024“…However, questions related to its mechanism of interaction with the substrate, furimazine, as well as bioluminescence activity remain elusive. Here, we combined molecular dynamics (MD) simulation and mutational analysis to show that the R162A mutation results in a decreased but stable <u>bioluminescence </u>activity of NLuc in living cells and in vitro. …”